SAFETY AND IMMUNOGENICITY OF TWO LOTS OF PNEUMOCOCCAL CONJUGATE VACCINE IN INFANTS. 1116

Article metrics

To optimize the safety and immunogenicity of pneumococcal conjugate vaccines (PCV), the following issues related to vaccine formulation need to be considered: the quantity of each serotype-specific polysaccharide (PS), total quantity of PS, total quantity of protein carrier, ratio of PS to carrier, and the carrier protein of concurrently administered Hib conjugate vaccines. We performed a study to evaluate some of these factors with two lots of a heptavalent PCV (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) employing the outer membrane protein complex (OMPC) of N. meningitidis serogroup B as the carrier. Compared to lot 1, lot 2 contained higher quantities of serotypes 6B, 18C, and 23F PS, and had more total PS and OMPC. At 2, 4, and 6 months of age, 40 infants were given PCV lot 1 concurrent with PRP-OMP (7.5μg dose at 2, 4 mo) and PRP-T (6 mo) (Grp A), 60 infants were given PCV lot 2 concurrent with HbOC (Grp B), and 60 infants were given PCV lot 2 concurrent with PRP-OMP (3 μg dose) (Grp C). No serious PCV-attributable adverse reactions were reported. In this study, a higher dose of PS conjugate did not enhance serotype-specific immune responses (see table). Concurrent use of PRP-OMP vaccine did not diminish the immune response of PCV, except for serotype 6B (Grp C). Both lots of PCV were immunogenic and are promising candidates for a vaccine efficacy trial to prevent invasive pneumococcal disease in infants. Supported by Merck & Co., Inc.

Table 1 Table 1

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Zangwill, K., Greenberg, D., Wong, V. et al. SAFETY AND IMMUNOGENICITY OF TWO LOTS OF PNEUMOCOCCAL CONJUGATE VACCINE IN INFANTS. 1116. Pediatr Res 39, 188 (1996) doi:10.1203/00006450-199604001-01138

Download citation